{"id":14984,"date":"2025-09-26T10:02:29","date_gmt":"2025-09-26T09:02:29","guid":{"rendered":"https:\/\/resemedicin.se\/reseradet\/?p=14984"},"modified":"2025-09-26T12:24:51","modified_gmt":"2025-09-26T11:24:51","slug":"2025-09-26-nirsevimab-77-skyddande-mot-rsv-sjukhusinlaggning-hos-spadbarn","status":"publish","type":"post","link":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-09-26-nirsevimab-77-skyddande-mot-rsv-sjukhusinlaggning-hos-spadbarn\/","title":{"rendered":"2025-09-26 Nirsevimab 77 % skyddande mot RSV-sjukhusinl\u00e4ggning hos sp\u00e4dbarn"},"content":{"rendered":"\n<p>En ny&nbsp;<a href=\"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2839288\" target=\"_blank\" rel=\"noreferrer noopener\">multinationell kohortstudie<\/a>&nbsp;fr\u00e5n RSV-s\u00e4songen&nbsp;2024\u201325&nbsp;visar att&nbsp;nirsevimab (Beyfortus)&nbsp;var&nbsp;77 % effektivtmot&nbsp;RSV-relaterad sjukhusinl\u00e4ggning&nbsp;hos sp\u00e4dbarn. Studien omfattade&nbsp;409 723 sp\u00e4dbarn&nbsp;i&nbsp;USA, Kanada, Libanon och Saudiarabien, med data ur&nbsp;Epic Cosmos&nbsp;(\u22481 700 sjukhus, 40 000 mottagningar). Totalt registrerades&nbsp;3 385 RSV-inl\u00e4ggningar, varav&nbsp;850&nbsp;bland nirsevimab-exponerade och&nbsp;2 535&nbsp;bland icke-exponerade. \u00c4ven&nbsp;IVA-inl\u00e4ggningar&nbsp;(324&nbsp;vs&nbsp;765) och&nbsp;intubationer&nbsp;(49&nbsp;vs&nbsp;90) var f\u00e4rre i den behandlade gruppen. F\u00f6rfattarna konkluderar att nirsevimab fortsatt minskar RSV-sjuklighet hos de minsta barnen.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>Reser\u00e5dets kommentar<\/strong><\/h5>\n\n\n\n<p>Resultaten st\u00f6djer ytterligare g\u00e4llande <a href=\"https:\/\/www.folkhalsomyndigheten.se\/contentassets\/a94c2f64405f4cc39a1ee241b4748e15\/allvarlig-rs-virusinfektion-bland-barn-och-vuxna-i-sverige-sammanfattande-kunskapsunderlag.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">svenska rekommendationer<\/a> med&nbsp;s\u00e4songsprofylax med nirsevimab&nbsp;f\u00f6r sp\u00e4dbarn under f\u00f6rsta RSV-s\u00e4songen och utvalda h\u00f6griskbarn inf\u00f6r andra s\u00e4songen.<\/p>\n\n\n\n<p style=\"font-size:12px\"><em><strong>EpiNytt\u00a0<\/strong><\/em>\u00e4r Reser\u00e5dets kostnadsfria omv\u00e4rldsbevakning med aktuell information om\u00a0utbrott och nyheter p\u00e5 vaccin- och resefronten. Se\u00a0<a href=\"https:\/\/resemedicin.se\/reseradet\/epinytt\/\">hela listan med nyheter i fulltext<\/a>. Dela g\u00e4rna l\u00e4nken med intresserade kolleger, vilka ocks\u00e5 sj\u00e4lva kan\u00a0<a href=\"https:\/\/resemedicin.se\/reseradet\/prenumerera-kostnadsfritt-pa-epinytt\/\">prenumerera p\u00e5 nyhetsbrevet<\/a>\u00a0utan kostnad.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>En ny&nbsp;multinationell kohortstudie&nbsp;fr\u00e5n RSV-s\u00e4songen&nbsp;2024\u201325&nbsp;visar att&nbsp;nirsevimab (Beyfortus)&nbsp;var&nbsp;77 % effektivtmot&nbsp;RSV-relaterad sjukhusinl\u00e4ggning&nbsp;hos sp\u00e4dbarn. Studien omfattade&nbsp;409 723 sp\u00e4dbarn&nbsp;i&nbsp;USA, Kanada, Libanon och Saudiarabien, med data ur&nbsp;Epic Cosmos&nbsp;(\u22481 700 sjukhus, 40 000 mottagningar). Totalt registrerades&nbsp;3 385 RSV-inl\u00e4ggningar, varav&nbsp;850&nbsp;bland nirsevimab-exponerade och&nbsp;2 535&nbsp;bland icke-exponerade. \u00c4ven&nbsp;IVA-inl\u00e4ggningar&nbsp;(324&nbsp;vs&nbsp;765) och&nbsp;intubationer&nbsp;(49&nbsp;vs&nbsp;90) var f\u00e4rre i den behandlade gruppen. F\u00f6rfattarna konkluderar att nirsevimab fortsatt minskar RSV-sjuklighet hos de minsta barnen. &hellip; <a href=\"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-09-26-nirsevimab-77-skyddande-mot-rsv-sjukhusinlaggning-hos-spadbarn\/\" class=\"more-link\">Forts\u00e4tt l\u00e4sa<span class=\"screen-reader-text\"> \u201d2025-09-26 Nirsevimab 77 % skyddande mot RSV-sjukhusinl\u00e4ggning hos sp\u00e4dbarn\u201d<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"aside","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-14984","post","type-post","status-publish","format-aside","hentry","category-epinytt","post_format-post-format-aside"],"modified_by":"Reser\u00e5det","jetpack_featured_media_url":"","jetpack-related-posts":[{"id":15925,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2026-02-02-rsv-profylax-nt-radets-rekommendation-om-beyfortus-kvarstar-aven-sasongen-2026-2027\/","url_meta":{"origin":14984,"position":0},"title":"2026-02-02 RSV-profylax: NT-r\u00e5dets rekommendation om Beyfortus\u00ae kvarst\u00e5r \u00e4ven s\u00e4songen 2026\/2027","author":"Reser\u00e5det","date":"2026-02-02","format":"aside","excerpt":"NT-r\u00e5dets nationella rekommendation f\u00f6r profylax mot RSV med den monoklonala antikroppen nirsevimab (Beyfortus\u00ae) f\u00f6r s\u00e4songen 2025\/2026 kommer att forts\u00e4tta g\u00e4lla \u00e4ven under RSV-s\u00e4songen 2026\/2027. Avtalet med l\u00e4kemedelsf\u00f6retaget har f\u00f6rl\u00e4ngts i syfte att s\u00e4kerst\u00e4lla fortsatt tillg\u00e5ng till l\u00e4kemedlet. Rekommendationen inneb\u00e4r att Beyfortus\u00ae \u00e4ven forts\u00e4ttningsvis ska anv\u00e4ndas f\u00f6r prevention av RSV-infektion hos\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":13818,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-06-05-nt-radet-beyfortus-till-riskbarn-infor-rsv-sasongen-2025-26\/","url_meta":{"origin":14984,"position":1},"title":"2025-06-05 NT-r\u00e5det: Beyfortus\u00ae till riskbarn inf\u00f6r RSV-s\u00e4songen 2025\/26","author":"Reser\u00e5det","date":"2025-06-05","format":"aside","excerpt":"Regionernas samverkansmodell f\u00f6r l\u00e4kemedel, NT-r\u00e5det, har i ett yttrande till regionerna rekommendera att Beyfortus (nirsevimab) ges som profylax mot RSV-infektion till barn f\u00f6dda fr\u00e5n och med 10 september 2025. Beyfortus ges vid f\u00f6rlossning\/BB-verksamhet antingen direkt efter f\u00f6dseln innan hemg\u00e5ng, eller vid ett ordinarie \u00e5terbes\u00f6k. NT-r\u00e5dets rekommendation till regionerna inf\u00f6r s\u00e4songen\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":14938,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-09-10-beyfortus-nirsevimab-till-nyfodda-i-sverige\/","url_meta":{"origin":14984,"position":2},"title":"2025-09-10 Beyfortus (nirsevimab) till nyf\u00f6dda i Sverige","author":"Reser\u00e5det","date":"2025-09-10","format":"aside","excerpt":"Fr\u00e5n och med\u00a0idag 10 september 2025\u00a0erbjuds nyf\u00f6dda i Sverige en eng\u00e5ngsdos av den l\u00e5ngverkande monoklonala antikroppen\u00a0nirsevimab (Beyfortus)\u00a0som skydd mot RSV. Administreringen sker p\u00e5 f\u00f6rlossning\/BB i anslutning till hemg\u00e5ng eller vid planerat \u00e5terbes\u00f6k, och insatsen avslutas n\u00e4r smittspridningen bed\u00f6ms ha avtagit under s\u00e4songen. Beslutet f\u00f6ljer NT-r\u00e5dets rekommendation inf\u00f6r s\u00e4songen 2025\/26 och\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":14951,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-09-14-rsv-vaccination-58-83-skydd-mot-sjukhusvard-hos-aldre\/","url_meta":{"origin":14984,"position":3},"title":"2025-09-14 RSV-vaccination: 58\u201383 % skydd mot sjukhusv\u00e5rd hos \u00e4ldre","author":"Reser\u00e5det","date":"2025-09-14","format":"aside","excerpt":"Tv\u00e5 nya real-world-studier visar att en dos RSV-vaccin ger betydande skydd mot sjukhusv\u00e5rd bland \u00e4ldre. I en dansk fas-4-studie (randomiserad \u00f6ppen pr\u00f6vning) under s\u00e4songen 2024\/25 uppskattades skyddseffekten f\u00f6r Abrysvo\u00ae hos personer >60 \u00e5r till\u00a083%\u00a0mot sjukhusinl\u00e4ggning f\u00f6r RSV-orsakad luftv\u00e4gssjukdom; \u00e4ven f\u00e4rre sjukhusinl\u00e4ggningar s\u00e5gs f\u00f6r RSV-nedre luftv\u00e4gsinfektion (VE 92 %) och f\u00f6r\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":15807,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2026-01-11-vinterns-luftvagsvirus-ah3n2-i-ny-tappning-och-rsv-pa-uppgang\/","url_meta":{"origin":14984,"position":4},"title":"2026-01-11 Vinterns luftv\u00e4gsvirus: A(H3N2) i ny tappning och RSV p\u00e5 uppg\u00e5ng","author":"Reser\u00e5det","date":"2026-01-12","format":"aside","excerpt":"Luftv\u00e4gsvirusaktiviteten har \u00f6kat tydligt i Europa under inledningen av 2026, med Iinfluensa\u00a0 som det dominerande viruset och med tecken till \u00f6kande RSV-cirkulation i flera l\u00e4nder. S\u00e4songen har startat tidigare \u00e4n normalt i stora delar av Europa och pr\u00e4glas av en omfattande spridning av influensa A, framf\u00f6r allt subtypen A(H3N2). Influensa\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2026\/01\/image-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2026\/01\/image-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2026\/01\/image-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2026\/01\/image-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2026\/01\/image-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2026\/01\/image-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":13570,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-05-25-arets-influensa-rsv-sasong-ar-over-i-europa-men-covid-19-mojligen-pa-vag-upp\/","url_meta":{"origin":14984,"position":5},"title":"2025-05-25 \u00c5rets influensa\/RSV-s\u00e4song \u00e4r \u00f6ver i Europa, men covid-19 m\u00f6jligen p\u00e5 v\u00e4g upp","author":"Reser\u00e5det","date":"2025-05-25","format":"aside","excerpt":"Data som rapporterades till ECDC vecka 20, 2025, tyder p\u00e5 att andelen patienter i EU\/EES-l\u00e4nderna som s\u00f6ker v\u00e5rd f\u00f6r luftv\u00e4gsinfektioner i prim\u00e4rv\u00e5rden eller v\u00e5rdas f\u00f6r sv\u00e5r luftv\u00e4gsinfektion (SARI) p\u00e5 sjukhus nu \u00e5terg\u00e5tt till en baslinjeniv\u00e5. Det uppt\u00e4cks ocks\u00e5 f\u00e5 fall av influensa i diagnostiska prover (<10% i samtliga l\u00e4nder). \u00c4ven\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/05\/image-12.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/05\/image-12.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/05\/image-12.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/05\/image-12.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/05\/image-12.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/05\/image-12.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts\/14984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/comments?post=14984"}],"version-history":[{"count":2,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts\/14984\/revisions"}],"predecessor-version":[{"id":15011,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts\/14984\/revisions\/15011"}],"wp:attachment":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/media?parent=14984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/categories?post=14984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/tags?post=14984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}